BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1319825)

  • 1. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy.
    Perera FP; Motzer RJ; Tang D; Reed E; Parker R; Warburton D; O'Neill P; Albertini R; Bigbee WL; Jensen RH
    Cancer Res; 1992 Jul; 52(13):3558-65. PubMed ID: 1319825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L; Moffat J; Martins H; Glickman B
    Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPRT and glycophorin A mutations in foundry workers: relationship to PAH exposure and to PAH-DNA adducts.
    Perera FP; Tang DL; O'Neill JP; Bigbee WL; Albertini RJ; Santella R; Ottman R; Tsai WY; Dickey C; Mooney LA
    Carcinogenesis; 1993 May; 14(5):969-73. PubMed ID: 8504491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study.
    Albertini RJ; Srám RJ; Vacek PM; Lynch J; Nicklas JA; van Sittert NJ; Boogaard PJ; Henderson RF; Swenberg JA; Tates AD; Ward JB; Wright M; Ammenheuser MM; Binkova B; Blackwell W; de Zwart FA; Krako D; Krone J; Megens H; Musilová P; Rajská G; Ranasinghe A; Rosenblatt JI; Rössner P; Rubes J; Sullivan L; Upton P; Zwinderman AH
    Res Rep Health Eff Inst; 2003 Jun; (116):1-141; discussion 143-62. PubMed ID: 12931846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
    Meng Q; Su T; O'Neill JP; Walker VE
    Environ Mol Mutagen; 2002; 39(4):282-95. PubMed ID: 12112380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
    Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular epidemiological studies in 1,3-butadiene exposed Czech workers: female-male comparisons.
    Albertini RJ; Sram RJ; Vacek PM; Lynch J; Rossner P; Nicklas JA; McDonald JD; Boysen G; Georgieva N; Swenberg JA
    Chem Biol Interact; 2007 Mar; 166(1-3):63-77. PubMed ID: 16949064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
    Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
    Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L
    Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycophorin A somatic cell mutation frequencies in Finnish reinforced plastics workers exposed to styrene.
    Bigbee WL; Grant SG; Langlois RG; Jensen RH; Anttila A; Pfäffli P; Pekari K; Norppa H
    Cancer Epidemiol Biomarkers Prev; 1996 Oct; 5(10):801-10. PubMed ID: 8896891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the effects of exposure on cleanup workers at the Chernobyl nuclear reactor accident using multiple end points.
    Moore DH; Tucker JD; Jones IM; Langlois RG; Pleshanov P; Vorobtsova I; Jensen R
    Radiat Res; 1997 Nov; 148(5):463-75. PubMed ID: 9355872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human in vivo somatic mutation measured at two loci: individuals with stably elevated background erythrocyte glycophorin A (gpa) variant frequencies exhibit normal T-lymphocyte hprt mutant frequencies.
    Bigbee WL; Fuscoe JC; Grant SG; Jones IM; Gorvad AE; Harrington-Brock K; Strout CL; Thomas CB; Moore MM
    Mutat Res; 1998 Feb; 397(2):119-36. PubMed ID: 9541637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression.
    Hashimoto H; Chatterjee S; Berger NA
    Cancer Res; 1995 Sep; 55(18):4029-35. PubMed ID: 7664276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
    Beland FA
    Res Rep Health Eff Inst; 1995 Oct; (72):1-27; discussion 29-39. PubMed ID: 11381742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequencies of HPRT- lymphocytes and glycophorin A variants erythrocytes in Fanconi anemia patients, their parents and control donors.
    Sala-Trepat M; Boyse J; Richard P; Papadopoulo D; Moustacchi E
    Mutat Res; 1993 Sep; 289(1):115-26. PubMed ID: 7689157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The L84F polymorphism in the O6-Methylguanine-DNA-Methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lymphocytes of tobacco smokers.
    Hill CE; Wickliffe JK; Guerin AT; Kinslow CJ; Wolfe KJ; Ammenheuser MM; Abdel-Rahman SZ
    Pharmacogenet Genomics; 2007 Sep; 17(9):743-53. PubMed ID: 17700363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.